Revel Pharmaceuticals

Revel Pharmaceuticals is a private, preclinical-stage biotech targeting the fundamental biology of aging and age-related diseases. The company's platform aims to develop therapies that clear toxic accumulations and repair damage, positioning it in the emerging longevity and chronic disease space. With a lean team and a scientific advisory board featuring experts in glycation and aging biology, Revel is building its foundational technology. The company is currently pre-revenue and focused on early-stage research and development.

Platform focused on developing biologic therapies to clear toxic proteins and metabolites (e.g., advanced glycation endproducts) that accumulate with age, aiming to repair cellular damage and reverse disease pathology.

Revel operates in the competitive and fast-evolving longevity biotech sector, competing with well-funded startups (e.g., Unity Biotechnology, Calico, Altos Labs) and large pharma exploring aging targets. Its differentiation hinges on the specific efficacy of its biologic clearance approach against chosen toxic metabolites like AGEs.